Pemphigoid Gestationis Management

Diagnostic Considerations

• The British Journal of Dermatology recommends prednisolone as the first-line systemic agent for pemphigoid gestationis due to its minimal fetal exposure, with a 90% inactivation by the placenta 2, 3, 4

First-Line Management

• The British Journal of Dermatology suggests that prednisolone is the preferred corticosteroid due to its limited placental transfer, minimizing fetal exposure 2, 3, 4
• For mild localized disease, the British Journal of Dermatology recommends considering superpotent topical corticosteroids on lesions only, though systemic therapy is usually required 5
• The Praxis Medical Insights guideline recommends combining prednisolone with antihistamines for symptomatic pruritus relief 1

Second-Line Adjunctive Therapy

• The British Journal of Dermatology states that azathioprine in combination with corticosteroids has been used successfully, with low teratogenicity risk 2, 3
• The British Journal of Dermatology notes that intravenous immunoglobulin (IVIg) is safe in pregnancy, with seven of eight severe pemphigus cases responding well without neonatal complications 2, 3

Postpartum Management

• The Praxis Medical Insights guideline warns that postpartum flares are expected and often require higher corticosteroid doses than during pregnancy 1
• The Praxis Medical Insights guideline recommends resuming or increasing oral prednisone to the previously effective dose, as pregnancy-related dose restrictions no longer apply 1

Breastfeeding Considerations

• The Praxis Medical Insights guideline states that prednisone/prednisolone is compatible with breastfeeding at doses ≤20 mg daily 1
• The British Journal of Dermatology advises that women should not breastfeed while receiving rituximab or for up to 12 months following the last infusion 2, 3

Obstetric Monitoring and Fetal Considerations

• The British Journal of Dermatology notes that pemphigoid gestationis is associated with fetal growth restriction and prematurity, requiring combined dermatology-obstetric care 2, 3
• The British Journal of Dermatology states that 45% of neonates may have transient pemphigus lesions at birth due to transplacental antibody transfer, resolving within 4 weeks spontaneously or with mild topical corticosteroids 2, 3

Common Pitfalls to Avoid

• The Praxis Medical Insights guideline warns against continuing to taper corticosteroids without confirmed diagnosis, as recurrence at low doses suggests inadequate dosing or misdiagnosis 1
• The Praxis Medical Insights guideline advises against assuming PUPPP if symptoms persist beyond 2 weeks postpartum, as this strongly favors pemphigoid gestationis 1
• The MMWR Recommendations and Reports guideline recommends avoiding the use of antimicrobial agents before the intrapartum period to treat colonization, as this is ineffective and may cause adverse consequences 6
• The Praxis Medical Insights guideline recommends avoiding prolonged use of high-potency topical corticosteroids during pregnancy 4, 7